Olanzapine (Zyprexa) vs Olanzapine (Zyprexa Relprevv)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT03510325 · Phase 3 · completed
This trial randomly assigned 762 people with schizophrenia to active antipsychotic treatments, with outcomes rated by masked assessors but treatment assignment itself not blinded. Among 111 participants who had not responded to first-line treatment and were reassigned to a second drug, 31.7% responded on olanzapine against 44.7% on amisulpride and 62.5% on clozapine, a significant difference across the three (p=0.03). Olanzapine was the least effective of the second-line options tested.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 (missed)
Result source: NCT03510325
Olanzapine (Zyprexa Relprevv)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00088478 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.
Reported efficacy
Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)
Result source: NCT00088478
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olanzapine (Zyprexa) | Olanzapine (Zyprexa Relprevv) |
|---|---|---|
| PANSS total, change | -8.8 vs 4.5−13.3 vs placeboNCT00686998 | —Not posted · NCT00088491 |
| CGI-S, change | —Not posted · NCT00083668 | -0.4 vs -0.3vs Oral OlanzapineNCT00320489 |
| PANSS response | 31.7% vs 44.7%avs amisulprideNCT03510325 | —Not posted · NCT00088491 |
| PSP, change | —Not posted · NCT00083668 | —Not posted · NCT00088491 |
| Relapse (% of patients) | —Not posted · NCT00083668 | 20.1% vs 18.5%vs Oral OlanzapineNCT00320489 |
PANSS total, change
- Olanzapine (Zyprexa)
- -8.8 vs 4.5−13.3 vs placeboNCT00686998
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
CGI-S, change
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
- Olanzapine (Zyprexa Relprevv)
- -0.4 vs -0.3vs Oral OlanzapineNCT00320489
PANSS response
- Olanzapine (Zyprexa)
- 31.7% vs 44.7%avs amisulprideNCT03510325
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
PSP, change
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
Relapse (% of patients)
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
- Olanzapine (Zyprexa Relprevv)
- 20.1% vs 18.5%vs Oral OlanzapineNCT00320489
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. Olanzapine (Zyprexa): 11 of 11 rows · Olanzapine (Zyprexa Relprevv): 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olanzapine (Zyprexa) | Olanzapine (Zyprexa Relprevv) |
|---|---|---|
| CGI-S absolute change · score No placebo or comparator arm | -0.17 score @ 313wka,b NCT00088465 · Phase 3 · registry result, not featured evidence | -0.17 score @ 313wka,b NCT00088465 · Phase 3 · registry result, not featured evidence |
| PANSS General Psychopathology absolute change · score No placebo or comparator arm | 0.19 score @ 330wka,b NCT00088465 · Phase 3 · registry result, not featured evidence | 0.19 score @ 330wka,b NCT00088465 · Phase 3 · registry result, not featured evidence |
| PANSS Negative absolute change · score No placebo or comparator arm | -0.08 score @ 330wka,b NCT00088465 · Phase 3 · registry result, not featured evidence | -0.08 score @ 330wka,b NCT00088465 · Phase 3 · registry result, not featured evidence |
| PANSS Positive absolute change · score No placebo or comparator arm | 0.21 score @ 330wka,b NCT00088465 · Phase 3 · registry result, not featured evidence | 0.21 score @ 330wka,b NCT00088465 · Phase 3 · registry result, not featured evidence |
| PANSS Total absolute change · score No placebo or comparator arm | 0.3 score @ 330wka,b NCT00088465 · Phase 3 · registry result, not featured evidence | 0.3 score @ 330wka,b NCT00088465 · Phase 3 · registry result, not featured evidence |
| QLS Total absolute change · score No placebo or comparator arm | 6.75 score @ 330wka,b NCT00088465 · Phase 3 · registry result, not featured evidence | 6.75 score @ 330wka,b NCT00088465 · Phase 3 · registry result, not featured evidence |
| SF-36 Physical Component Summary absolute change · score No placebo or comparator arm Physical component summary | -0.36 score @ 329wka,b Physical component summary NCT00088465 · Phase 3 · registry result, not featured evidence | -0.36 score @ 329wka,b Physical component summary NCT00088465 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 63.4%Olanzapine/Intense Behavioral Weigc NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results55.9%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 38.2% NCT00190749 · Phase 4 · registry result, not featured evidence 60.3% NCT00088465 · Phase 3 · registry result, not featured evidence 0% NCT00797277 · Phase 3 · registry result, not featured evidence 22%Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence 34.2%Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination 31.5%Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 18.2% NCT00686998 · Phase 2 · registry result, not featured evidence —Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence —3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence | 54.9%c NCT00320489 · Phase 3 · monotherapy show 1 more result60.3% NCT00088465 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 14.9%Olanzapine/Intense Behavioral Weigc NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results18.6%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 0% NCT00190749 · Phase 4 · registry result, not featured evidence 8.3% NCT00088465 · Phase 3 · registry result, not featured evidence — NCT00797277 · Phase 3 · registry result, not featured evidence 4%Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence 10.5%Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination 5.5%Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 4.5% NCT00686998 · Phase 2 · registry result, not featured evidence —Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence —3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence | 9.8%c NCT00320489 · Phase 3 · monotherapy show 1 more result8.3% NCT00088465 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 19.8%Olanzapine/Intense Behavioral Weigc NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results12.7%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT00190749 · Phase 4 · registry result, not featured evidence 18.3% NCT00088465 · Phase 3 · registry result, not featured evidence 0% NCT00797277 · Phase 3 · registry result, not featured evidence —Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence —Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination —Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 0% NCT00686998 · Phase 2 · registry result, not featured evidence 0%Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence 3.2%Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence 0%Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence 0%3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination 25%0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination 5.9%Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence | 9.5%c NCT00320489 · Phase 3 · monotherapy show 1 more result18.3% NCT00088465 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | c somnolence 23.8% weight increased 20.8% headache 19.8% NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more resultsweight increased 30.4% headache 18.6% somnolence 18.6% NCT00982020 · Phase 4 · registry result, not featured evidence · combination weight increased 16.2% headache 10.3% sedation 10.3% NCT00190749 · Phase 4 · registry result, not featured evidence weight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence insomnia 10% somnolence 8% increased appetite 6% NCT00401973 · Phase 3 · registry result, not featured evidence somnolence 6.6% dry mouth 5.3% insomnia 5.3% NCT00401973 · Phase 3 · registry result, not featured evidence · combination diarrhoea 13.7% somnolence 11% nausea 6.8% NCT00401973 · Phase 3 · registry result, not featured evidence · combination weight increased 40.9% (placebo 0%) increased appetite 18.2% (placebo 2.4%) somnolence 18.2% (placebo 2.4%) NCT00686998 · Phase 2 · registry result, not featured evidence injection site irritation 6.9% injection site pain 6.9% psychotic disorder 6.9% NCT06319170 · Phase 1 · registry result, not featured evidence injection site pain 9.7% somnolence 9.7% blood creatine phosphokinase increased 6.5% NCT06319170 · Phase 1 · registry result, not featured evidence alanine aminotransferase increased 6.5% aspartate aminotransferase increased 6.5% somnolence 6.5% NCT06319170 · Phase 1 · registry result, not featured evidence 3 mg abnormal lab values 33.3% decreased appetite 16.7% depression 16.7% NCT00512070 · Phase na · registry result, not featured evidence · combination 0.3 mg abnormal lab values 50% depression 25% psychotic symptoms 25% NCT00512070 · Phase na · registry result, not featured evidence · combination abnormal lab values 29.4% insomnia/sleep disturbance 23.5% diarrhea 17.6% NCT00512070 · Phase na · registry result, not featured evidence | show 1 more resultweight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olanzapine (Zyprexa)
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 9 further endpoints in the CSV export.
Olanzapine (Zyprexa Relprevv)
+ 8 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa)'s landscape · Olanzapine (Zyprexa Relprevv)'s landscape